• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Cascadian Therapeutics Gets Pediatric Investigation Plan Waiver for Lead Candidate

    Bryan Mc Govern
    Jan. 02, 2018 09:18AM PST
    Pharmaceutical Investing

    Cascadian Therapeutics received a pediatric waiver from the European Medicines Agency (EMA) for their lead candidate tucatinib, currently in a trial treating HER2+ metastatic breast cancer.

    Cascadian Therapeutics (NASDAQ:CASC) received a pediatric waiver from the European Medicines Agency (EMA) for their lead candidate tucatinib, currently in a trial treating HER2+ metastatic breast cancer.
    As quoted in the press release:

    “This pediatric waiver is another important milestone in the European regulatory process, and will allow Cascadian to submit a marketing authorization application for tucatinib for the treatment of HER2+ metastatic breast cancer to the EMA following completion of the HER2CLIMB pivotal trial, without the requirement to conduct clinical studies in the pediatric population prior to approval or post-approval,” said Scott D. Myers, President and Chief Executive Officer of Cascadian Therapeutics.
    As part of the regulatory process for the registration of new medicines with the EMA, pharmaceutical companies are required to have in place an approved Pediatric Investigation Plan (PIP) prior to MAA filing that outlines the clinical development strategy for studying the investigational product in the pediatric population. In some instances, a waiver from required pediatric studies for certain conditions may be granted by the EMA when development of a medicine for use in children is not feasible or appropriate.

    Click here to read the full press release.

    Source: globenewswire.com

    pharmaceutical investingeuropean medicines agencymarketing authorization\breast cancermetastatic breast cancermarketing authorization applicationclinical studies
    The Conversation (0)

    Go Deeper

    AI Powered
    Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

    Top 5 Small-cap Pharma Stocks of 2025

    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×